CN112469408A - 利鲁唑前药治疗阿尔茨海默氏病的用途 - Google Patents

利鲁唑前药治疗阿尔茨海默氏病的用途 Download PDF

Info

Publication number
CN112469408A
CN112469408A CN201980048687.7A CN201980048687A CN112469408A CN 112469408 A CN112469408 A CN 112469408A CN 201980048687 A CN201980048687 A CN 201980048687A CN 112469408 A CN112469408 A CN 112469408A
Authority
CN
China
Prior art keywords
patient
riluzole
administered
disease
prodrug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980048687.7A
Other languages
English (en)
Chinese (zh)
Inventor
V·科里克
R·伯曼
I·库雷希
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baiaohaifen Therapeutics Co ltd
Original Assignee
Baiaohaifen Therapeutics Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baiaohaifen Therapeutics Co ltd filed Critical Baiaohaifen Therapeutics Co ltd
Publication of CN112469408A publication Critical patent/CN112469408A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201980048687.7A 2018-07-22 2019-07-20 利鲁唑前药治疗阿尔茨海默氏病的用途 Pending CN112469408A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862701814P 2018-07-22 2018-07-22
US62/701,814 2018-07-22
PCT/US2019/042718 WO2020023324A1 (en) 2018-07-22 2019-07-20 Use of riluzole prodrugs to treat alzheimer's disease

Publications (1)

Publication Number Publication Date
CN112469408A true CN112469408A (zh) 2021-03-09

Family

ID=69181140

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980048687.7A Pending CN112469408A (zh) 2018-07-22 2019-07-20 利鲁唑前药治疗阿尔茨海默氏病的用途

Country Status (15)

Country Link
US (1) US12161633B2 (https=)
EP (1) EP3823616A4 (https=)
JP (2) JP2021530543A (https=)
KR (1) KR20210034621A (https=)
CN (1) CN112469408A (https=)
AU (1) AU2019310013B2 (https=)
BR (1) BR112021000768A2 (https=)
CA (1) CA3107215A1 (https=)
EA (1) EA202190308A1 (https=)
IL (1) IL280177B2 (https=)
MX (2) MX2021000515A (https=)
NZ (1) NZ772009A (https=)
PH (1) PH12021550043A1 (https=)
SG (1) SG11202100385YA (https=)
WO (1) WO2020023324A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023165465A1 (zh) * 2022-03-01 2023-09-07 暨南大学 利鲁唑在治疗少精症中的应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230027189A (ko) * 2020-06-24 2023-02-27 바이오하벤 테라퓨틱스 리미티드 강박 장애를 치료하기 위한 조성물 및 방법
EP4240308A4 (en) * 2020-10-05 2024-10-30 Icahn School of Medicine at Mount Sinai Riluzole for the treatment of alzheimer's disease
EP4277624B1 (en) * 2021-01-18 2026-01-14 Biohaven Therapeutics Ltd. Troriluzole for use in the treatment of alzheimer's disease of mild severity
WO2022178425A1 (en) * 2021-02-22 2022-08-25 Yale University Targeted bifunctional degraders

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016140878A2 (en) * 2015-03-03 2016-09-09 Biohaven Pharmaceutical Holding Company Ltd. Prodrugs riluzole and their method of use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214663B2 (en) * 2000-06-14 2007-05-08 Medarex, Inc. Tripeptide prodrug compounds
JP2008518935A (ja) * 2004-11-01 2008-06-05 セオ ホン ユー 筋萎縮性側索硬化症の神経退行を減少させるための方法及び組成物
FR2957077B1 (fr) * 2010-03-02 2012-04-13 Univ Dauvergne Clermont I Utilisation du riluzole pour traiter ou prevenir les effets indesirables d'agents anti-cancereux
EP3079692A4 (en) 2013-12-09 2017-10-18 Thomas Jefferson University Novel methods of treating a neurodegenerative disease in a mammal in need thereof
WO2016085998A1 (en) * 2014-11-26 2016-06-02 Medicinova, Inc. Combination of ibudilast and riluzole and methods of using same
WO2017201502A1 (en) * 2016-05-20 2017-11-23 Biohaven Pharmaceutical Holding Company Ltd. Use of glutamate modulating agents with immunotherapies to treat cancer
WO2018031707A1 (en) * 2016-08-10 2018-02-15 Biohaven Pharmaceutical Holding Company Ltd. Acyl benzo[d]thiazol-2-amine and their methods of use
AU2019223014B2 (en) * 2018-02-21 2024-10-17 Orphai Therapeutics Inc. Combination therapy with apilimod and glutamatergic agents
EP4277624B1 (en) * 2021-01-18 2026-01-14 Biohaven Therapeutics Ltd. Troriluzole for use in the treatment of alzheimer's disease of mild severity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016140878A2 (en) * 2015-03-03 2016-09-09 Biohaven Pharmaceutical Holding Company Ltd. Prodrugs riluzole and their method of use
CN107567438A (zh) * 2015-03-03 2018-01-09 拜尔哈文制药股份有限公司 利鲁唑前药及其用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023165465A1 (zh) * 2022-03-01 2023-09-07 暨南大学 利鲁唑在治疗少精症中的应用

Also Published As

Publication number Publication date
EP3823616A1 (en) 2021-05-26
US20210290599A1 (en) 2021-09-23
SG11202100385YA (en) 2021-02-25
EA202190308A1 (ru) 2021-05-19
BR112021000768A2 (pt) 2021-05-11
NZ772009A (en) 2026-02-27
WO2020023324A1 (en) 2020-01-30
IL280177A (en) 2021-03-01
EP3823616A4 (en) 2022-05-04
IL280177B1 (en) 2024-09-01
IL280177B2 (en) 2025-01-01
MX2021000515A (es) 2021-06-08
US12161633B2 (en) 2024-12-10
KR20210034621A (ko) 2021-03-30
CA3107215A1 (en) 2020-01-30
PH12021550043A1 (en) 2021-09-20
JP2021530543A (ja) 2021-11-11
AU2019310013A1 (en) 2021-02-11
AU2019310013B2 (en) 2025-01-02
JP2025093952A (ja) 2025-06-24
MX2024010655A (es) 2024-09-11

Similar Documents

Publication Publication Date Title
US12161633B2 (en) Use of riluzole prodrugs to treat alzheimer's disease
Ayoub et al. Assessment of cognitive and neural recovery in survivors of pediatric brain tumors in a pilot clinical trial using metformin
Hannestad et al. Changes in the cholinergic system between bipolar depression and euthymia as measured with [123I] 5IA single photon emission computed tomography
KR102171747B1 (ko) 알츠하이머 병 치료를 위한 방법 및 약품
Reid et al. A placebo‐controlled screening trial of olanzapine, valproate, and coenzyme Q10/L‐carnitine for the treatment of cocaine dependence
US20100178362A1 (en) Chromium complexes for improvement of memory and cognitive function
Vidoni et al. Safety and target engagement profile of two oxaloacetate doses in Alzheimer's patients
US20240082340A1 (en) Use of riluzole prodrugs to treat alzheimer's disease
TW202339763A (zh) 用於治療多種疾病之組成物及方法
Lee et al. Cognitive function improvement effects of gintonin-enriched fraction in subjective memory impairment: An assessor-and participant-blinded placebo-controlled study
Simonsen et al. Illustrated pharmacology for nurses
US12201618B2 (en) Use of riluzole prodrugs to treat Alzheimer's disease
Wang et al. Exploratory study on the safety and effectiveness of Yizhi Qingxin Decoction (capsules) in the treatment of hypertension in the elderly with mild cognitive impairment (deficiency of kidney essence syndrome)
González-González et al. Automedicación para la prevención del covid-19 en estudiantes universitarios del noreste de méxico
AU2023286504A1 (en) Cyclobenzaprine treatment for post-acute sequelae of (sars)-cov-2 infection (pasc)
CN120051284A (zh) 用于治疗早期阿尔茨海默病的方法
EA049330B1 (ru) Применение пролекарств рилузола для лечения болезни альцгеймера
Ochoa-Orozco et al. “Chasing the Dragon”: A Fatal Case Report of Toxic Leucoencéphalopathie Due to Inhaled Heroin
US20250375459A1 (en) Methods for ameliorating cognitive impairment using bile acid derivatives
Kim et al. Efficacy and safety of oral SOCG in treatment of major depressive disorder: A protocol for a phase II, randomized, double-blind, placebo controlled, parallel-groups, dose finding exploratory study
US20240016783A1 (en) Riluzole for the treatment of alzheimer's disease
Ramos-Quiroga et al. Comparative Bioavailability of Methylphenidate Powder for Prolonged-Release Oral Suspension and Methylphenidate Prolonged-Release Chewable Tablets versus Methylphenidate Immediate-Release Tablets: Phase 1, Single-Dose, Randomised, Crossover Studies in Healthy Adults
Tariot P. 4.017 Memantine/donepezil dual-therapy is superior to placebo/donepezil therapy for treatment of moderate to severe Alzheimer's disease
WO2025194109A1 (en) Compositions and methods for improving brain function
CN118613265A (zh) 用于治疗神经变性疾病的胆汁酸和苯基丁酸化合物的组合

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination